INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO ® (teriparatide [rDNA origin] ...

BIRMINGHAM, Ala. – The osteoporosis drug Forteo works better than Fosamax to strengthen bones in arthritis patients with prednisone-induced osteoporosis, according to a new study from a researcher at ...

Forteo (teriparatide) is a brand-name drug that doctors prescribe for some people with osteoporosis. It contains proteins that strengthen bones and stimulate new bone growth. A typical prescription is ...

WASHINGTON, June 12 (UPI) -- A study released Monday reveals Eli Lilly's osteoporosis treatment Forteo is not cost-effective when compared to Merck's Fosamax, and experts said the findings may have ...

Teva Pharmaceuticals has received the Food and Drug Administration’s approval for generic Forteo. The product is expected to be available in the coming weeks. “We are thrilled to receive the ...

PARSIPPANY, N.J. & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a ...

DUBLIN--(BUSINESS WIRE)--The "Forteo - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Forteo - API Insight, 2019 provides product and API manufacturers' details ...

The clutter in my parents' kitchen sometimes gives me clues about their health that I don't get through more direct means. When either of them gets sick, for instance, the counter usually reserved for ...

In a head-to-head comparison of the two drugs, Forteo increased lumbar spine density measurements by 7.2 percent compared to 3.4 percent for Fosamax, and it boosted hip density measurements by 3.8 ...